Subtype-selective phosphodiesterase PET ligands

亚型选择性磷酸二酯酶 PET 配体

基本信息

  • 批准号:
    10568308
  • 负责人:
  • 金额:
    $ 78.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-01-01 至 2027-11-30
  • 项目状态:
    未结题

项目摘要

Project Summary. As a major cAMP-specific hydrolyzing enzyme, PDE7 plays a significant role in modulating immune and inflammatory response in a variety of neurodegenerative diseases, including Alzheimer’s disease (AD). PDE7 treatment not only improved the memory and behavior in transgenic models of AD but also exhibited decreased brain Aβ deposition, enhanced Aβ degradation, and decreased tau phosphorylation. The mechanism of action was mediated via the cAMP-specific neuroinmmune response in AD. Positron emission tomograohy (PET) is capable of quantifying biochemical processes in vivo, and a suitable PDE7 ligand would substantially improve our understanding of such cAMP-mediated signaling under different pathophysiological AD conditions, otherwise inaccessible by ex vivo (destructive) analysis. Quantification of PDE7 in living brain by PET would also provide the assessment of distribution, target engagement and dose occupancy of new PDE7-targeted neurotherapeutics. To date, no successful examples have been demonstrated to image PDE7 in human, representing a significant deficiency of our ability to study this target in vivo. Therefore, we propose to develop a novel PDE7 PET ligand that can fill this void as the first successful and translational imaging tool. We are the first groups to develop PDE7-specific ligands in cross-species PET studies, including [11C]P7-2104 developed in 2021. However, this ligand was discontinued due to marginal binding specificity in vivo. In our 2nd generation, we identified a lead molecule, P7-2526, which showed high binding affinity and excellent selectivity. Our preliminary evaluation confirmed that we have overcome the two major obstacles for PDE7 ligand development by achieving: 1) substantially-improved binding affinity, representing the best compound to date; and 2) high target specificity (characteristic high uptake in PDE7-rich striatum and low in PDE7-poor cerebellum/pons, which was validated by LC-MS and Western blotting). Though P7-2526 is a promising lead for new PDE7-targeted ligands, further optimization for improved binding specificity with proper brain kinetics are sought for translational cross-species (rodents and nonhuman primates) imaging studies to achieve optimal PDE7 quantification for drug discovery and clinical translation for AD patients. On the basis that P7-2526 serves a validated lead for medicinal chemistry optimization, as specific goals, we will design and prepare a focused library of PDE7-specific modulators amenable for labeling with 11C or 18F, and evaluate their ability to quantify PDE7 activity and changes during drug challenge in rodents and nonhuman primates, as well as autoradiography and biological validation in postmortem human brain tissues. The impact of this work is not only to develop the first successful high-affinity and selective PDE7 PET ligand for the study of neurodegenerative disease- related biological processes, but also ultimately, via PET imaging validation in higher species, to advance this ligand for potential clinical translation and monitor target response of novel neurotherapeutics for neurodegenerative diseases, including AD.
项目摘要。作为一种主要的 cAMP 特异性水解酶,PDE7 在调节 多种神经退行性疾病的免疫和炎症反应,包括阿尔茨海默病(AD)。 PDE7 治疗不仅改善了 AD 转基因模型的记忆和行为,而且表现出下降 大脑 Aβ 沉积,增强 Aβ 降解,减少 tau 磷酸化。作用机制是 AD 中通过 cAMP 特异性神经免疫反应介导。正电子发射断层扫描 (PET) 能够 量化体内生化过程,合适的 PDE7 配体将​​大大提高我们的理解 在不同的病理生理学 AD 条件下,这种 cAMP 介导的信号传导的研究,否则无法通过体外方法获得 (破坏性)分析。通过 PET 对活体大脑中 PDE7 进行定量还可以提供分布评估, 新型 PDE7 靶向神经治疗药物的靶点参与和剂量占用。迄今为止,还没有成功的例子 已被证明可以对人类 PDE7 进行成像,这表明我们研究这一能力的严重缺陷 体内目标。因此,我们建议开发一种新型 PDE7 PET 配体来填补这一空白,作为第一个成功的 和平移成像工具。 我们是第一批在跨物种 PET 研究中开发 PDE7 特异性配体的团队,包括 [11C]P7-2104 于 2021 年开发。然而,由于体内结合特异性有限,该配体已停产。在我们的第二 在一代中,我们鉴定了一个先导分子 P7-2526,它表现出高结合亲和力和优异的选择性。我们的 初步评估证实,我们已经克服了PDE7配体开发的两大障碍: 实现:1)显着提高的结合亲和力,代表迄今为止最好的化合物; 2)高目标 特异性(富含 PDE7 的纹状体特征性高摄取,而缺乏 PDE7 的小脑/脑桥则低摄取,这是 通过 LC-MS 和蛋白质印迹验证)。尽管 P7-2526 是新的 PDE7 靶向配体的有希望的先导,但进一步 寻求优化以提高结合特异性和适当的脑动力学,以实现跨物种的转化 (啮齿类动物和非人类灵长类动物)成像研究,以实现药物发现的最佳 PDE7 定量 AD 患者的临床翻译。 在 P7-2526 为药物化学优化提供经过验证的先导化合物的基础上,作为具体目标,我们将 设计和制备适合用 11C 或 18F 标记的 PDE7 特异性调节剂的重点库,并评估 他们还能够量化啮齿动物和非人类灵长类动物药物挑战期间 PDE7 活性和变化 作为死后人脑组织的放射自显影和生物验证。这项工作的影响不仅 开发第一个成功的高亲和力和选择性PDE7 PET配体,用于神经退行性疾病的研究- 相关的生物过程,但最终,通过高等物种的 PET 成像验证,以推进这种配体 用于潜在的临床转化并监测神经退行性新型神经疗法的目标反应 疾病,包括 AD。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven H Liang其他文献

Ru-Photoredox-Catalyzed Decarboxylative Oxygenation of Aliphatic Carboxylic Acids through N-(acyloxy)phthalimide
Ru-光氧化还原催化 N-(酰氧基)邻苯二甲酰亚胺对脂肪族羧酸进行脱羧氧化
  • DOI:
    10.1021/acs.orglett.8b01885
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Chao Zheng;Yuting Wang;Yangrui Xu;Zhen Chen;Guangying Chen;Steven H Liang
  • 通讯作者:
    Steven H Liang

Steven H Liang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven H Liang', 18)}}的其他基金

Subtype-Selective Metabotropic Glutamate Receptor PET Ligands
亚型选择性代谢型谷氨酸受体 PET 配体
  • 批准号:
    10576674
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
Glycogen synthase kinase 3 ligand discovery for Alzheimer’s disease
糖原合成酶激酶 3 配体发现治疗阿尔茨海默病
  • 批准号:
    10637434
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
Subtype-selective NMDA ligands for Alzheimer's Disease
阿尔茨海默病的亚型选择性 NMDA 配体
  • 批准号:
    10593906
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
In vivo Probe for ionotropic glutamate signaling system: AMPA receptors
离子型谷氨酸信号系统体内探针:AMPA 受体
  • 批准号:
    10584340
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
Subtype-selective NMDA ligands for Alzheimer's Disease
阿尔茨海默病的亚型选择性 NMDA 配体
  • 批准号:
    10355691
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
PET ligand discovery for arginine vasopressin
精氨酸加压素的 PET 配体发现
  • 批准号:
    10641669
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
PET imaging of ionotropic glutamate receptor signaling in Alzheimer's disease
阿尔茨海默病中离子型谷氨酸受体信号传导的 PET 成像
  • 批准号:
    10574694
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
PET ligand discovery for arginine vasopressin
精氨酸加压素的 PET 配体发现
  • 批准号:
    10356395
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
PET Imaging for neuroinflammation in Alzheimer's disease
阿尔茨海默病神经炎症的 PET 成像
  • 批准号:
    10653556
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
PET imaging for neuroimmune function in Alzheimer's disease
PET 成像研究阿尔茨海默病的神经免疫功能
  • 批准号:
    10474697
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了